GETT
24.6.2021 13:02:14 CEST | Business Wire | Press release
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, today announced it is furthering its efforts to enable its clients to reduce CO2 emissions by delivering sustainable transportation options for its enterprise clients and their employees.
Gett’s platform now allows enterprise clients in the UK to adopt an employee travel policy consisting solely of electric fleets running 24 hours a day in central London, thus enabling companies to better track, control and reduce CO2 emissions from business travel. Gett has been able to extend this service through both more TX Electric taxis and more fleet partners, including Ola and Green Tomato who provide eco-travel options for business clients.
This new platform capability complements Gett’s existing Gett Green program in the United Kingdom. Through its existing partnership with EcoAct, Gett helps offset enterprise clients’ annual CO2 emissions from vehicle rides. EcoAct’s CO2 offsetting program is based on three accredited projects: wind power generation in India, peatland conservation and restoration, and Cambodian rainforest protection. Each project aligns to specific Sustainable Development Goals (SDGs) as Gett supports its enterprise clients in achieving a more sustainable future. In addition, B2C riders can select from numerous eco-travel options available on the Gett app—Gett Electric (to ride in a TX Electric taxi) and Gett Green (to donate 20p from total ride fare to help fund green projects in London). In May 2021, Gett signed a new Gett Green partner, Trees for Cities. Trees for Cities is a London-based environmental charity that has planted more than one million trees to improve air quality in urban areas. For more on Gett Green and Gett’s commitment to sustainability, visit Gett’s website .
Dave Waiser, CEO and co-founder of Gett, said: “We are delighted to offer more sustainability initiatives at Gett as we strive to reduce CO2 emissions and support our enterprise clients in achieving their sustainability goals. With corporate travel resuming, businesses have greater responsibility for employee transportation. As a global platform, we are in the fortunate position to take action to reduce the impact of pollution in the cities we love and provide businesses travelers with more sustainable transportation choices.”
About Gett
Gett is a technology platform focused on corporate Ground Transportation Management (GTM) in a market worth $100B globally. Gett is the GTM category leader and serves more than a quarter of Fortune 500 companies. Gett’s cloud-based software aggregates existing transportation providers onto a single platform, and helps business manage all their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally. Gett organizes corporate fleet, ride-hailing, taxi, and limo providers on one platform and optimizes the entire employee experience, from booking and riding to invoicing and analytics, to save businesses time and money. Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005431/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom